TNF and juvenile idiopathic arthritis: In summary, based on the results of our study, we presume that the assessment of serum levels of TNF-α in children with JIA during treatment with TNF-α inhibitors (etanercept or adalimumab) is not a reliable biomarker of disease activity or immunological remission.